Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) EBIT Margin: 2014-2025

Historic EBIT Margin for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -56.70%.

  • Viridian Therapeutics, Inc.\DE's EBIT Margin rose 9701307.00% to -56.70% in Q3 2025 from the same period last year, while for Sep 2025 it was -463.52%, marking a year-over-year increase of 9325900.00%. This contributed to the annual value of -99,018.21% for FY2024, which is 1798318.00% down from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's EBIT Margin is -56.70%, which was up 99.96% from -142,356.00% recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's EBIT Margin peaked at -56.70% during Q3 2025, and registered a low of -142,356.00% during Q2 2025.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's EBIT Margin averaged around -90,539.37%, with its median value being -97,069.77% (2024).
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by 7,077,795bps in 2023, then skyrocketed by 9,701,307bps in 2025.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's EBIT Margin stood at -13,589.25% in 2021, then crashed by 3,314,027bps to -46,729.52% in 2022, then tumbled by 5,254,548bps to -99,275.00% in 2023, then crashed by 2,221,389bps to -121,488.89% in 2024, then skyrocketed by 9,701,307bps to -56.70% in 2025.
  • Its EBIT Margin stands at -56.70% for Q3 2025, versus -142,356.00% for Q2 2025 and -130,369.44% for Q1 2025.